These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20606604)

  • 1. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).
    Hoogduijn MJ; Popp FC; Grohnert A; Crop MJ; van Rhijn M; Rowshani AT; Eggenhofer E; Renner P; Reinders ME; Rabelink TJ; van der Laan LJ; Dor FJ; Ijzermans JN; Genever PG; Lange C; Durrbach A; Houtgraaf JH; Christ B; Seifert M; Shagidulin M; Donckier V; Deans R; Ringden O; Perico N; Remuzzi G; Bartholomew A; Schlitt HJ; Weimar W; Baan CC; Dahlke MH;
    Transplantation; 2010 Jul; 90(2):124-6. PubMed ID: 20606604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.
    Dahlke MH; Hoogduijn M; Eggenhofer E; Popp FC; Renner P; Slowik P; Rosenauer A; Piso P; Geissler EK; Lange C; Chabannes D; Mazzanti B; Bigenzahn S; Bertolino P; Kunter U; Introna M; Rambaldi A; Capelli C; Perico N; Casiraghi F; Noris M; Gotti E; Seifert M; Saccardi R; Verspaget HW; van Hoek B; Bartholomew A; Wekerle T; Volk HD; Remuzzi G; Deans R; Lazarus H; Schlitt HJ; Baan CC;
    Transplantation; 2009 Sep; 88(5):614-9. PubMed ID: 19741455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells can affect solid organ allograft survival.
    Popp FC; Eggenhofer E; Renner P; Geissler EK; Piso P; Schlitt HJ; Dahlke MH
    Transplantation; 2009 May; 87(9 Suppl):S57-62. PubMed ID: 19424009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients.
    Crop MJ; Baan CC; Korevaar SS; Ijzermans JN; Alwayn IP; Weimar W; Hoogduijn MJ
    Transplantation; 2009 Mar; 87(6):896-906. PubMed ID: 19300194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression by mesenchymal stromal cells: from culture to clinic.
    Jones BJ; McTaggart SJ
    Exp Hematol; 2008 Jun; 36(6):733-41. PubMed ID: 18474304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation.
    Crop M; Baan C; Weimar W; Hoogduijn M
    Transpl Int; 2009 Apr; 22(4):365-76. PubMed ID: 19000235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function.
    Renner P; Eggenhofer E; Rosenauer A; Popp FC; Steinmann JF; Slowik P; Geissler EK; Piso P; Schlitt HJ; Dahlke MH
    Transplant Proc; 2009; 41(6):2607-11. PubMed ID: 19715984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry.
    Martins AA; Paiva A; Morgado JM; Gomes A; Pais ML
    Transplant Proc; 2009 Apr; 41(3):943-6. PubMed ID: 19376394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
    Zhou H; Guo M; Bian C; Sun Z; Yang Z; Zeng Y; Ai H; Zhao RC
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):403-12. PubMed ID: 19925878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials.
    Brooke G; Rossetti T; Pelekanos R; Ilic N; Murray P; Hancock S; Antonenas V; Huang G; Gottlieb D; Bradstock K; Atkinson K
    Br J Haematol; 2009 Feb; 144(4):571-9. PubMed ID: 19077161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells: immunobiology and therapeutic potential in kidney disease.
    McTaggart SJ; Atkinson K
    Nephrology (Carlton); 2007 Feb; 12(1):44-52. PubMed ID: 17295660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells for therapeutic purposes.
    Sensebé L; Bourin P
    Transplantation; 2009 May; 87(9 Suppl):S49-53. PubMed ID: 19424006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?
    Zonta S; De Martino M; Bedino G; Piotti G; Rampino T; Gregorini M; Frassoni F; Dal Canton A; Dionigi P; Alessiani M
    Transplant Proc; 2010 May; 42(4):1336-40. PubMed ID: 20534295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease.
    Leal A; Ichim TE; Marleau AM; Lara F; Kaushal S; Riordan NH
    Cell Immunol; 2008; 253(1-2):11-5. PubMed ID: 18627903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
    Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.
    Maccario R; Podestà M; Moretta A; Cometa A; Comoli P; Montagna D; Daudt L; Ibatici A; Piaggio G; Pozzi S; Frassoni F; Locatelli F
    Haematologica; 2005 Apr; 90(4):516-25. PubMed ID: 15820948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.
    Villaron EM; Almeida J; López-Holgado N; Alcoceba M; Sánchez-Abarca LI; Sanchez-Guijo FM; Alberca M; Pérez-Simon JA; San Miguel JF; Del Cañizo MC
    Haematologica; 2004 Dec; 89(12):1421-7. PubMed ID: 15590390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G.
    Nasef A; Mathieu N; Chapel A; Frick J; François S; Mazurier C; Boutarfa A; Bouchet S; Gorin NC; Thierry D; Fouillard L
    Transplantation; 2007 Jul; 84(2):231-7. PubMed ID: 17667815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion.
    Wang Y; Zhang A; Ye Z; Xie H; Zheng S
    Transplant Proc; 2009 Dec; 41(10):4352-6. PubMed ID: 20005397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure.
    Ohnishi S; Nagaya N
    Am J Nephrol; 2007; 27(3):301-7. PubMed ID: 17460394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.